Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.

@article{Moore2016EffectivenessO1,
  title={Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.},
  author={Matthew Robert Moore and Ruth Link-Gelles and William Schaffner and Ruth Lynfield and Corinne Holtzman and Lee H. Harrison and Shelley M. Zansky and Jennifer B. Rosen and Arthur L. Reingold and Karen Scherzinger and A Regelski Thomas and Ramon Emmanuel Guevara and Tasneem Motala and Jeffrey T. Eason and Meghan M Barnes and Susan Petit and M. Matthews N. Farley and Lesley Mcgee and J. Helms. Jorgensen and Cynthia G. Whitney},
  journal={The Lancet. Respiratory medicine},
  year={2016},
  volume={4 5},
  pages={
          399-406
        }
}
BACKGROUND In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended in the USA for prevention of invasive pneumococcal disease in children. Licensure was based on immunogenicity data comparing PCV13 with the earlier seven-valent formulation. Because clinical endpoints were not assessed for the new antigens, we did a postlicensure matched case-control study to assess vaccine effectiveness. METHODS Cases in children aged 2-59 months were identified through active… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 12 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
VIEW 4 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Eff ect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

W ner
  • Lancet Infect Dis 2015;
  • 2015

ABCs report : Streptococcus pneumoniae

IH Park, MR Moore, JJ Treanor
  • 2010

Clinical review of biologics license application for Prevnar 13 (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein))

T. Khoie
  • Silver Spring, MD: US Food and Drug Administration,
  • 2010

Similar Papers